Cochrane · systematic review · CD002954
Drugs for discoid lupus erythematosus
Jessop, S, Whitelaw, DA, Grainge, MJ, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
SkinAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
25
current version
GRADE rated
7
No studies
15
Included studies
NR
No studies 15 · 60%Ungraded 3 · 12%Very low 0 · 0%Low 3 · 12%Moderate 4 · 16%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Fluocinonide 0.05% compared with hydrocortisone 1%
Population: people with discoid lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearing or excellent improvement (after 6 weeks of treatment) Fluocinonide 0.05% vs hydrocortisone 1% | no estimate extracted | 1 study · 78 participants | Low Downgraded: risk of bias, imprecision |
At least 50% reduction in erythema Fluocinonide 0.05% vs hydrocortisone 1% | no estimate extracted | NR | No studies |
Quality of life measure Fluocinonide 0.05% vs hydrocortisone 1% | no estimate extracted | NR | No studies |
Relapse Fluocinonide 0.05% vs hydrocortisone 1% | no estimate extracted | NR | No studies |
Adverse events of medication, leading to discontinuation or significant morbidity Fluocinonide 0.05% vs hydrocortisone 1% | no estimate extracted | 1 study · 78 participants | Moderate Downgraded: risk of bias, imprecision |
Acitretin 50 mg daily compared with hydroxychloroquine 400 mg daily
Population: people with discoid lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearing or excellent improvement (after 8 weeks of treatment) Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily | no estimate extracted | 1 study · 58 participants | Low Downgraded: risk of bias, imprecision |
At least 50% reduction in erythema (after 8 weeks of treatment) Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily | no estimate extracted | 1 study · 49 participants | Low Downgraded: risk of bias, imprecision |
Quality of life measure Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily | no estimate extracted | NR | No studies |
Relapse Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily | no estimate extracted | NR | No studies |
Adverse events of medication, leading to discontinuation or significant morbidity Acitretin 50 mg daily vs hydroxychloroquine 400 mg daily | no estimate extracted | 1 study · 58 participants | Moderate Downgraded: risk of bias, imprecision |
Pimecrolimus 1% compared with betamethasone 17‐valerate 0.1%
Population: people with discoid lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearing or excellent improvement (after 8 weeks of treatment) Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% | no estimate extracted | 1 study · 10 participants | Ungraded |
At least 50% reduction in erythema Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% | no estimate extracted | NR | No studies |
Quality of life measure Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% | no estimate extracted | NR | No studies |
Relapse Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% | no estimate extracted | NR | No studies |
Adverse events of medication, leading to discontinuation or significant morbidity Pimecrolimus 1% vs betamethasone 17‐valerate 0.1% | no estimate extracted | NR | No studies |
R‐salbutamol 0.5% topical cream compared with placebo
Population: people with discoid lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearing or excellent improvement R‐salbutamol 0.5% topical cream vs placebo | no estimate extracted | 1 study · 37 participants | Ungraded |
At least 50% reduction in erythema R‐salbutamol 0.5% topical cream vs placebo | no estimate extracted | 1 study · 37 participants | Ungraded |
Quality of life measure R‐salbutamol 0.5% topical cream vs placebo | no estimate extracted | NR | No studies |
Relapse R‐salbutamol 0.5% topical cream vs placebo | no estimate extracted | NR | No studies |
Adverse events of medication, leading to discontinuation or significant morbidity R‐salbutamol 0.5% topical cream vs placebo | no estimate extracted | 1 study · 37 participants | Moderate Downgraded: imprecision |
Tacrolimus 0.1% cream compared with placebo
Population: people with discoid lupus erythematosus
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clearing or excellent improvement Tacrolimus 0.1% cream vs placebo | no estimate extracted | NR | No studies |
At least 50% reduction in erythema Tacrolimus 0.1% cream vs placebo | no estimate extracted | NR | No studies |
Quality of life measure Tacrolimus 0.1% cream vs placebo | no estimate extracted | NR | No studies |
Relapse Tacrolimus 0.1% cream vs placebo | no estimate extracted | NR | No studies |
Adverse events of medication, leading to discontinuation or significant morbidity Tacrolimus 0.1% cream vs placebo | no estimate extracted | 1 study · 14 participants | Moderate Downgraded: imprecision |